92 Targeting Mixed Lineage Leukemia Histone Methylases for Novel Cancer Therapy

Wednesday, November 4, 2009: 2:40 PM
Kohlberg (Camino Real Hotel)
Subhrangsu S. Mandal , Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX
Khairul Ansari , Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX
Increasing amounts of evidence suggest that antisense therapy holds a strong promise for the treatment of various types of cancer. Genes associated with apoptosis, cell proliferation and signaling are already been targeted using specific antisense for treatment of different types of cancer and many of them are in clinical trial. Mixed lineage leukemias (MLLs) are human histone methyl-transferases (HMTs) that play critical roles in gene activation and epigenetics. MLLs are often associated with oncogenic transformation.  Recent studied from our laboratory demonstrated that MLL histone methylases play critical roles in gene expression and cell cycle regulation. Most importantly, we explored the potential of MLLs in developing novel targeted cancer therapy. Our results demonstrated that knockdown of MLL histone methylase induced tumor selective apoptosis in cultured cancer cells and suppressed the colon cancer growth in vivo demonstrating their strong potential toward novel cancer therapy. Notably, the material presented in this document is under US patent application (pending).